title: [Current views on the interaction between the treatment of osteoporosis and cardiovascular diseases].
abstract: The most common medical conditions after menopause are osteoporosis and atherosclerotic disease. Traditionally these two conditions were considered unrelated and their coexistence has been attributed to independent processess exclusively reated to age. The possible link between cardiovascular disease and osteoporosis stimulates today to analyse not only the evidence of a possible association, but also to identify mutual beneficial and adverse effects of drugs used in these two diseases. That's why, the focus on the interference between osteoporosis treatment and drugs used for atherosclerosis is made. Moreover side effects of cardiological drug considering bones are analysed. Additionally possible advantages of selected drugs used for cardiovascular diseases on osteoporosis prevention are evaluated. Drugs used for osteoporosis treatment may heave adverse effects on cardiovascular system. The article has detailed analyses of current drug classes, such as the bisphosphonates, strontium ranelate as well as a review of the controversy surrounding hormone replacement therapy (HRT) and the selective oestrogen receptor modulators (SERMs). Lastly discussion of adverse effects on the heart of calcium and drugs influencing calcium metabolism such as vitamin D, parathormone and calcitonin is performed.
authors.affiliation: Katedra i Klinika Kardiologii, Uniwersytet Medyczny, Lublin, e-mail: zapolia@wp.pl.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Zapolski
authors.affiliation: Katedra i Klinika Kardiologii, Uniwersytet Medyczny, Lublin.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Wysokiński
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001842:Bone and Bones / Q000187:drug effects; D002116:Calcitonin / Q000009:adverse effects / Q000627:therapeutic use; D002136:Calcium, Dietary / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000188:drug therapy*; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006321:Heart / Q000187:drug effects; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy*; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use; D014807:Vitamin D / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D013876:Thiophenes; C081587:strontium ranelate; D014807:Vitamin D; D002116:Calcitonin
keywords:  cardiology;  complications ;  pharmacotherapy; osteoporosis